For the quarter ended June 2024, MannKind (MNKD) reported revenue of $72.39 million, up 48.9% over the same period last year. EPS came in at $0.05, compared to $0.00 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $62.8 million, representing a surprise of +15.26%. The company delivered an EPS surprise of +400.00%, with the consensus EPS estimate being $0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ex ...

MannKind (MNKD) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 400%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.02 per share when it actually produced earnings of $0.05, delivering a surprise of 150%.Over the last four quarters, the ...

EXHIBIT 99.1 mannkind MANNKIND CORPORATION REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 9:00 a.m. (ET) • 2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023 • YTD 2024 Total revenues of $139M; +55% vs. YTD 2023 • YTD 2024 Net income of $9 million; Non-GAAP net income of $29 million • Advances two orphan lung programs to human studies o MNKD-101 Phase 3 clinical trial activities initiated o MNKD-201 Phase 1 clinical trial on schedule to re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Delaware 13-3607736 (State or other jurisdiction of inc ...

2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial activities initiatedMNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended June  ...

LearnAboutNTM.com provides information and resources for patients and caregiversSite launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today the launch of an educational website designed to raise awareness of nontu ...

LearnAboutNTM.com provides information and resources for patients and caregiversSite launch in support of World NTM Awareness Day, August 4 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today the launch of an educational website designed to raise awareness of nont ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference c ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, August 7, 2024. A press release detailing the quarterly results will be issued the same day approximately one hour prior to the webcast. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time for investors, media, and the general public. Participating in the conference ...